Brain Injury RESEARCH
Evaluating Treatment of Aggression, Agitation, and Irritability
A phase 2, placebo-controlled study to assess the efficacy, safety and tolerability or AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of aggression, agitation, irritability in patients with traumatic brain injury (TBI).
Funded by: Avanir Pharmaceuticals (MLR-786-US-0295-0719)
Sheryl Katta-Charles, MD View Biography